Histamine and Bradykinin Pharmacology

Correct Answer

B — Cimetidine

Rationale

Cimetidine is the only H2 blocker classified as a clinically significant cytochrome P450 inhibitor. It inhibits multiple cytochrome P450 enzymes, raising plasma concentrations of co-administered drugs metabolized by these enzymes. The three highest-yield interactions are with warfarin, phenytoin, and theophylline. Famotidine and nizatidine have no clinically significant cytochrome P450 inhibitory activity. Ranitidine was withdrawn from the United States market in 2020 due to N-nitrosodimethylamine contamination and is no longer available.

Correct Answer

D — Famotidine

Rationale

Famotidine is the most potent H2 blocker currently in clinical use. It lacks the cytochrome P450 inhibitory activity of cimetidine and the antiandrogenic effects of cimetidine, making it the preferred H2 blocker for most patients. Cimetidine was the first H2 blocker introduced but is less potent than famotidine and carries significant drug interaction and adverse effect liabilities. Nizatidine has intermediate potency. Ranitidine was withdrawn from the United States market in 2020.

Correct Answer

A — Ranitidine

Rationale

Ranitidine was withdrawn from the United States market in 2020 following the discovery that N-nitrosodimethylamine — a probable human carcinogen — was generated as a degradation product during storage. Ranitidine is no longer available in the United States; the testable facts are the drug name, the year of withdrawal, and the contaminant. Cimetidine, famotidine, and nizatidine remain available and were not affected by this contamination issue.

Correct Answer

C — Omeprazole

Rationale

Omeprazole is a proton pump inhibitor — it irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical membrane of gastric parietal cells. Famotidine, cimetidine, and nizatidine are all H2 blockers — competitive reversible antagonists at the parietal cell H2 receptor. These two classes act at different points in the acid secretion pathway and differ in the completeness of acid suppression they produce.

Correct Answer

B — Warfarin

Rationale

Warfarin is an anticoagulant whose hepatic metabolism is reduced by cimetidine-mediated cytochrome P450 inhibition, raising plasma warfarin levels and increasing the risk of bleeding. Theophylline is a bronchodilator, not an anticoagulant — it is also affected by cimetidine but belongs to a different drug class. Phenytoin is an antiseizure drug that is similarly affected by cimetidine but belongs to a different drug class. Omeprazole is a proton pump inhibitor and is not subject to this interaction with cimetidine.

Correct Answer

D — Glucagon

Rationale

Glucagon activates adenylyl cyclase through its own glucagon receptor, which is independent of the beta-adrenergic receptor. In patients taking beta-blockers, epinephrine cannot produce bronchodilation through the beta-2 adrenergic pathway because those receptors are blocked. Glucagon bypasses this blockade by raising cyclic adenosine monophosphate via the glucagon receptor, producing bronchodilation and positive cardiac chronotropy. Famotidine is an H2 blocker. Diphenhydramine is an H1 antihistamine. Dantrolene is a ryanodine receptor blocker used for malignant hyperthermia and neuroleptic malignant syndrome.

Correct Answer

A — The imidazole ring of cimetidine coordinates to the heme iron of cytochrome P450 enzymes, blocking the active site

Rationale

Cimetidine contains an imidazole ring that coordinates directly to the heme iron at the active site of cytochrome P450 enzymes. This interaction blocks the enzyme's ability to oxidize its substrates, reducing the hepatic metabolism of co-administered drugs and raising their plasma concentrations. The inhibition is competitive and reversible — not irreversible alkylation. Famotidine and nizatidine lack the imidazole ring and do not produce this interaction to a clinically significant degree. Cimetidine does not reduce hepatic blood flow; its inhibition is a direct enzyme-level interaction.

Correct Answer

C — Cimetidine binds androgen receptors and acts as an androgen antagonist, directly blocking testosterone signaling at target tissues

Rationale

Cimetidine has direct affinity for androgen receptors and acts as an androgen antagonist independent of its acid-suppressing activity. At standard therapeutic doses in men, this receptor-level blockade produces gynecomastia and impotence, both of which are reversible on discontinuation. The correct management is to switch to famotidine, which has no affinity for androgen receptors and no antiandrogenic effects. The estrogen metabolism hypothesis via cytochrome P450 inhibition is mechanistically plausible but is not the established primary mechanism — the androgen receptor antagonism is direct. Leydig cell H2 receptors and dietary zinc are not established mechanisms for cimetidine-induced gynecomastia.

Correct Answer

B — Famotidine lacks the cytochrome P450 inhibitory activity and antiandrogenic effects of cimetidine, avoiding the drug interactions and hormonal adverse effects that cimetidine produces

Rationale

Famotidine is preferred over cimetidine primarily because it lacks two of cimetidine's off-target properties: it does not inhibit cytochrome P450 enzymes and does not bind androgen receptors. In a patient on multiple medications, cimetidine's broad cytochrome P450 inhibition would raise plasma levels of co-administered warfarin, phenytoin, theophylline, and other drugs, creating interaction hazards. Famotidine avoids all of this while providing equivalent or greater H2 receptor blockade. Both agents are competitive reversible H2 receptor antagonists — neither is irreversible. Famotidine is primarily renally eliminated rather than hepatically metabolized, meaning it actually requires dose reduction in renal impairment.

Correct Answer

D — H2 blockers are competitive reversible antagonists that can be overcome by high histamine concentrations, while proton pump inhibitors irreversibly inhibit the proton pump at the final common step of all stimulatory pathways

Rationale

H2 blockers compete with histamine at the H2 receptor in a reversible, surmountable manner — at high histamine drive, as occurs in Zollinger-Ellison syndrome, H2 blockade can be overwhelmed, and acid secretion continues. Proton pump inhibitors covalently and irreversibly inhibit the hydrogen-potassium ATPase, the proton pump that is the final common step for all three stimulatory pathways (histamine, gastrin, and acetylcholine). Because this inhibition is irreversible and acts downstream of all receptor signaling, no amount of upstream stimulation can restore acid output until new proton pump protein is synthesized. This mechanistic difference explains why proton pump inhibitors are superior for erosive esophagitis, Zollinger-Ellison syndrome, and Helicobacter pylori eradication regimens. H2 blockers do partially blunt gastrin- and acetylcholine-driven acid secretion indirectly, because both stimuli work partly by driving enterochromaffin-like cell histamine release onto parietal cells — and H2 blockade interrupts that paracrine step. However, gastrin and acetylcholine also act directly on their own parietal cell receptors independent of histamine, so H2 blockade cannot fully prevent their effects. The more complete explanation for the efficacy difference is the competitive reversible nature of H2 antagonism, which can be overcome by high histamine drive, versus the irreversible final-common-step inhibition that proton pump inhibitors provide.

Correct Answer

A — Proton pump inhibitors provide more complete and sustained acid suppression, which optimizes the bactericidal activity of the antibiotics used in eradication regimens

Rationale

Standard Helicobacter pylori eradication regimens consist of a proton pump inhibitor plus two antibiotics (typically clarithromycin and amoxicillin, or metronidazole). The proton pump inhibitor component is chosen because near-complete acid suppression raises intragastric pH, which enhances the stability and bactericidal activity of the antibiotics at the gastric mucosal surface where Helicobacter pylori resides. H2 blockers provide only partial acid suppression and are insufficient for this purpose. H2 blockers have no direct antibacterial activity against Helicobacter pylori. The cytochrome P450 interaction is specific to cimetidine and is not a class-wide property. Proton pump inhibitors do not inhibit Helicobacter pylori urease; their role in eradication is purely as acid suppressants.

Correct Answer

C — H2 receptors on cardiac myocytes and certain vascular beds contribute to anaphylaxis-associated tachycardia and vasodilation; H2 blockade covers these effects that H1 blockade alone cannot address

Rationale

Histamine acts at both H1 and H2 receptors during anaphylaxis. H1 receptor activation produces vasodilation, increased vascular permeability, urticaria, and bronchoconstriction. H2 receptor activation on cardiac myocytes contributes to tachycardia, and H2 receptors in certain vascular beds also contribute to vasodilation. Because H1 antihistamines do not block H2 receptors, H1 blockade alone leaves these cardiovascular histamine effects unaddressed. Adding famotidine (H2 blocker) alongside diphenhydramine (H1 blocker) provides broader histamine receptor coverage as an adjunct after epinephrine. The hierarchy remains unchanged: epinephrine is first-line and the only agent that reverses the full multimediator syndrome. H2 blockers do not inhibit mast cell degranulation and do not cross the blood-brain barrier to block central H2 receptors in any clinically meaningful way for anaphylaxis management.

Correct Answer

B — Cimetidine inhibits cytochrome P450 enzymes responsible for theophylline metabolism, raising theophylline plasma levels into the toxic range

Rationale

Theophylline is metabolized by cytochrome P450 enzymes in the liver. Cimetidine inhibits these enzymes via its imidazole ring, reducing theophylline clearance and causing plasma levels to rise. Theophylline has a narrow therapeutic index — the difference between therapeutic and toxic concentrations is small — so even a modest rise in plasma levels produces toxicity manifest as nausea, cardiac arrhythmias, and seizures. The correct response is to discontinue cimetidine and switch to famotidine, which has no cytochrome P450 inhibitory activity, and to monitor theophylline levels closely. Plasma protein displacement, renal tubular competition, and toxic metabolite formation are not established mechanisms for this interaction.

Correct Answer

D — H2 blockers are primarily renally excreted; reduced renal clearance causes drug accumulation to plasma levels that produce adverse effects

Rationale

As a class, H2 blockers — including famotidine, cimetidine, and nizatidine — are primarily excreted by the kidney. When renal function is reduced, drug clearance falls and plasma concentrations rise beyond the intended therapeutic range. Dose reduction or extended dosing intervals are required to maintain appropriate drug exposure. Famotidine is the most clinically relevant example because it is the most widely used H2 blocker in current practice. H2 blockers do not produce nephrotoxic metabolites and do not inhibit renal prostaglandin synthesis to a clinically significant degree. Their elimination pathway is renal excretion of the parent drug, not hepatic metabolism to active metabolites.

Correct Answer

D — Glucagon activates adenylyl cyclase through its own glucagon receptor, raising cyclic adenosine monophosphate and producing bronchodilation independently of the blocked beta-adrenergic receptor

Rationale

Beta-blockers such as metoprolol occupy beta-adrenergic receptors and prevent epinephrine from producing beta-2-mediated bronchodilation, even at high epinephrine doses. Glucagon bypasses this blockade entirely by acting on the glucagon receptor, a Gs-coupled receptor that activates adenylyl cyclase and raises cyclic adenosine monophosphate through a pathway entirely separate from the beta-adrenergic system. The resulting rise in cyclic adenosine monophosphate relaxes bronchial smooth muscle, producing bronchodilation. Glucagon also has positive inotropic and chronotropic effects via this mechanism, which can help support cardiac output in beta-blocker-treated anaphylaxis. Glucagon does not block H1 receptors, does not displace beta-blockers from adrenergic receptors, and does not act through muscarinic pathways.

Correct Answer

B — The massively elevated gastrin levels in Zollinger-Ellison syndrome drive histamine release that overwhelms famotidine's competitive reversible H2 blockade; a proton pump inhibitor is required because its irreversible inhibition cannot be overcome by upstream stimulation

Rationale

In Zollinger-Ellison syndrome, a gastrin-secreting tumor produces extremely high gastrin concentrations that continuously stimulate enterochromaffin-like cells to release histamine at rates that overwhelm competitive H2 blockade. Because H2 blockers are reversible competitive antagonists, sufficient histamine can displace the drug from its receptor and restore acid secretion. Proton pump inhibitors are first-line for Zollinger-Ellison syndrome because their irreversible inhibition of the hydrogen-potassium ATPase acts at the final common step downstream of all stimulatory pathways — no amount of gastrin, histamine, or acetylcholine can restore proton pump activity until new enzyme is synthesized. Famotidine does not require hepatic activation; it is active as the parent compound. Gastrinoma cells do not express H2 receptors in a way that produces tolerance. Gastrin acts partly through enterochromaffin-like cell histamine release and partly via direct parietal cell cholecystokinin-2 receptors, but in both cases the proton pump is the final common target that proton pump inhibitors block irreversibly.

Correct Answer

A — Famotidine does not inhibit cytochrome P450 enzymes and does not raise warfarin plasma levels; the elevated international normalized ratio is not explained by the H2 blocker and requires investigation for another cause

Rationale

Famotidine has no clinically significant cytochrome P450 inhibitory activity. Unlike cimetidine, it does not raise the plasma concentrations of warfarin or other drugs metabolized by cytochrome P450 enzymes. Therefore, the rise in international normalized ratio in this patient cannot be attributed to a famotidine-warfarin drug interaction, and another explanation must be sought — such as a dietary change in vitamin K intake, an unreported medication addition, an over-the-counter supplement, or an underlying medical change. If this patient had been started on cimetidine rather than famotidine, cimetidine's cytochrome P450 inhibition would be the likely explanation. Famotidine does not alter warfarin absorption through acid suppression or displace it from plasma proteins.

Correct Answer

C — For mild to moderate gastroesophageal reflux disease without mucosal erosions, partial acid suppression from H2 blockade is sufficient to relieve symptoms; complete suppression with a proton pump inhibitor is not required when there is no erosive disease to heal

Rationale

The choice between H2 blockers and proton pump inhibitors in gastroesophageal reflux disease depends on disease severity. For mild to moderate symptoms without endoscopic evidence of erosive esophagitis, the partial acid suppression provided by H2 blockade is adequate to relieve heartburn and regurgitation. Proton pump inhibitors are required when there is erosive esophagitis, because healing damaged esophageal mucosa requires near-complete and sustained acid suppression that H2 blockers cannot consistently provide. H2 blockers do not irreversibly suppress acid secretion — they are competitive reversible antagonists. The pharmacological rationale for drug selection here is the absence of erosive disease — the severity of mucosal damage, not the adverse effect profile of the drugs, drives the choice between partial and complete acid suppression. H2 blockers do not reduce lower esophageal sphincter tone; they act at the parietal cell H2 receptor to reduce acid output.